Core Viewpoint - PolyPid Ltd. is a late-stage biopharma company focused on improving surgical outcomes through innovative drug delivery systems [3]. Group 1: Company Overview - PolyPid Ltd. (Nasdaq: PYPD) specializes in locally administered, controlled, prolonged-release therapeutics using its proprietary PLEX technology [3]. - The lead product candidate, D-PLEX100, is currently in Phase 3 clinical trials aimed at preventing abdominal colorectal surgical site infections [3]. - The company is also in preclinical stages testing OncoPLEX for treating solid tumors, starting with glioblastoma [3]. Group 2: Upcoming Events - PolyPid's management will present at the 37th Annual ROTH Conference in Dana Point, California, on March 17-18, 2025 [1]. - A fireside chat will be available on-demand starting March 17, 2025, at 2:00 PM PT [1]. - The management team will engage in one-on-one investor meetings during the conference [2].
PolyPid to Participate in the 37th Annual ROTH Conference